ChemT Biotechnology, a startup aiming to revolutionize biologics manufacturing with AI-designed small molecules, has secured $4.0M in seed funding.
The company, founded by a team of biopharma experts, AI specialists, and serial entrepreneurs, is the first globally to apply this approach to tackle the industry's persistent challenges of high production costs and variable quality. Its flagship small molecule compound has already demonstrated a 5-10x yield increase and improved quality in both in vitro and in vivo settings.
